Foundation fighting blindness fund sells $2.75m in Opus Genetics stock
Covered in this story
What has happened since
- Opus Genetics is down 4.4% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $IRD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Opus Genetics →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.